Novel Electroceutical Approach for Neuromodulation of the Kidney as a Treatment for Hypertension

In 2017, 19% of all deaths in Minnesota were due to heart disease, and 3.6% of all adults reported that they’ve had a heart attack. Also, in 2017, 24% of all adults in Minnesota self-reported having hypertension (high blood pressure). Despite the $55.9 billion in costs related to the treatment of hypertension from 2014 to 2015, lifestyle modifications and drug-based therapies have only had moderate success and up to 50% of patients seeking treatment for hypertension are resistant or non-compliant to drug therapy.

Hypertension is the leading risk factor for cardiovascular diseases such as stroke, heart failure, and heart attacks. The inadequate management of hypertension and lack of new anti-hypertensive drugs in development has created a desperate need for non-pharmacological device-based therapies to effectively and affordably treat patients. Arthur de la Cruz-Lynch’s research project aims to develop a specialized renal nerve cuff with Heraeus Medical Components, which can electrically block renal nerve activity, in a non-destructive, reversible, and titratable. Such devices have the potential to improve the quality of life for all individuals with hypertension and establish Minnesota as a national leader in autonomic neuromodulation.

Graduate Fellow: Arthur de la Cruz-LynchIntegrative Biology & Physiology

Mentor: John Osborn, Ph.D.Surgery